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See Article, pages 125–132Autoimmunity occurs when genetically predisposed individuals
are exposed to environmental factors that trigger immune
responses to self-antigens. The immune system protects the host
by recognising and removing invading pathogens and damaged
cells and to do this efﬁciently it must be able to discriminate
between infected or damaged cells and healthy self-tissue. This
tolerance of self involves both central, thymic mechanisms and
peripheral pathways involving regulatory T cells (Treg) (Fig. 1)
[1]. Regulatory T cells are a subpopulation of T cells which down-
regulate immune responses, maintain tolerance to self-antigens
and prevent the development of autoimmunity. CD4 Treg,
deﬁned by high levels of CD25, low levels of CD127, and expres-
sion of the transcription factor FOXP3, comprise 1–5% of circulat-
ing T cells in humans [2]. FOXP3, which regulates their
development, is required for suppressive function and mice and
human lacking functional FOXP3 develop multiorgan autoimmu-
nity which in humans takes the form of the IPEX syndrome [3]. It
is thus logical to look for defective Treg function in autoimmune
hepatitis, an archetypal autoimmune disease [4]. Although previ-
ous studies reported reduced numbers and defective Treg func-
tion in AIH [5–7], Peiseler et al. now report normal frequencies
and function of Treg in patients with type 1 AIH; indeed they
found higher Treg frequencies in blood and liver tissue during
active disease compared with remission. How can these different
reports be reconciled?
One explanation is the use of better Treg markers in the cur-
rent study. Earlier studies used CD25 expression to deﬁne Treg
but CD25 is also expressed on effector CD4 T cells. Peiseler
et al. used low levels of CD127 and FOXP3 demethylation to accu-
rately distinguish Treg from effector T cells. In humans, FOXP3 is
transiently upregulated during T cell activation but constitutive
expression, which is necessary for Treg function, requires
demethylation of CpG dinucleotides at the FOXP3 locus providing
an epigenetic marker to discriminate between Treg and effector T
cells [8]. They also quantiﬁed Treg within the liver and conﬁrmed
previous ﬁndings that intrahepatic Treg frequencies mirror thoseJournal of Hepatology 20
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reduced frequency of Treg underlies immune escape in AIH.
If Treg are dysfunctional, this could explain failed immune
suppression in the presence of normal numbers. Unlike some pre-
vious studies, the current paper failed to detect functional defects
in Treg during active AIH or during remission. However, a recent
study suggests that a combination of reduced Tim-3 levels on
effector T cells and Gal9 on Treg renders effector cells resistant
to Treg control in AIH [10] implicating defective T cell activation
as well as Treg in the failed immune regulation. This draws par-
allels with studies reporting defective T cell regulation in chronic
viral hepatitis [11,12]. Thus, conventional assays of Treg function
may be too simplistic to detect speciﬁc defects. An additional
confounding factor may arise from studying Treg from blood
rather than within tissues where they operate. Most published
studies show increased hepatic inﬁltration of Treg in AIH and
the relevant cells may have been recruited from the blood into
tissue in response to inﬂammation. The complex cellular and
cytokine environment of the inﬂamed liver may have profound
effects on Treg differentiation, stability, and function as well as
altering the susceptibility of effector T cells to suppression. In
murine models, Treg appear to be functional and stable in the
inﬂamed environment [13] but human hepatic Treg show low
levels of phosphorylated STAT-5 consistent with impaired IL-2
receptor signalling [9]. This might be a consequence of reduced
secretion or increased consumption of IL-2 within the inﬂamed
liver. Furthermore, Treg in tissue interact with other cells includ-
ing dendritic and stromal cells which may affect their survival
and function and together with local cytokines could repro-
gramme Treg to express either Tbet and a Th1 phenotype [14]
or RORc and a Th-17 phenotype [15].
Thus, understanding the role of Treg in disease depends on
better methods to study their interactions and functions within
the tissue microenvironment. The normal liver contains specia-
lised antigen-presenting cells, including hepatic dendritic cells
and endothelial cells, that promote Treg generation and the pres-
ence of TGF-b, IL-10 and retinoic acid further promote the gener-
ation and survival of Treg [16]. Such a network may be important
to maintain immune homeostasis in the face of gut-derived anti-
gens. This tolerogenic environment is disrupted in hepatitis when
the innate immune response to local tissue injury and inﬂamma-12 vol. 57 j 6–8
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Fig. 1. Regulatory T cell recruitment to the inﬂamed liver. An initial inﬂux of innate immune cells including NK and NKT leads to the release of IFNc which upregulates
CXCR3 ligands and cell adhesion molecules on hepatic sinusoidal endothelium. Consequently, effector T cells and T regulatory cells are recruited via the inﬂamed hepatic
sinusoids and migrate beyond the endothelium to sites of liver inﬂammation in the portal tracts or hepatic parenchyma. Regulatory T cells are attracted to dendritic cells
which modulate their local function and survival. Effector cells cause damage to hepatocytes resulting in interface and lobular hepatitis. Inﬁltrating T cells, macrophages
and stromal cells secrete IFNc, TNFa and other proinﬂammatory cytokines that result in a microenvironment that promotes the persistence of chronic inﬂammation. CD4
regulatory T cells can suppress effector cell proliferation and function by secreting immunosuppressive cytokines (IL-10, TGFb) or through contact dependent mechanisms
to restore immune homeostasis and promote resolution of hepatitis. The balance of regulatory T cell and effector T cell function will determine whether hepatitis persists or
resolves. The fact that Tregs are detected at high frequencies in the liver of patients with AIH suggests that suppression of function locally rather than a basic defect in Treg
generation or function underlies the persistence of chronic autoimmune hepatitits.
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tion is followed by the recruitment of effector and regulatory
lymphocytes which both use the chemokine receptor CXCR3 to
respond to interferon-inducible chemokine ligands at sites of
active hepatitis and enter the inﬂamed liver [17,9,18].
In type 2 AIH, Treg recognise the same autoantigen as effector
T cells although the autoantigens in type 1 AIH remain unknown
[6]. It is possible that any defects could be conﬁned to the anti-
gen-speciﬁc Treg population within the liver and thus not readily
detectable by measuring global Treg function in blood. Whether
local suppression requires the presence of antigen-speciﬁc Treg
or can be mediated by non-speciﬁc mechanisms remains
unknown but is critical for the success of Treg therapy. Another
confounding factor is the use of immunosuppressive therapy to
treat AIH. In the present study, patients who had untreated active
disease had higher frequencies of Treg and effector T cells com-
pared with those with active disease on treatment and those in
remission, demonstrating the importance of assessing Treg in
untreated patients wherever possible.
What are the therapeutic implications of these ﬁndings?
Clinical trials show efﬁcacy of Treg infusions in clinical GVHD
after allogeneic stem cell transplantation [19] and using them
to restore immune homeostasis in AIH without the need for
toxic immunosuppressive therapy is an attractive option. The
ﬁnding that functional Treg in AIH are present in blood and
liver suggests that therapeutic success will depend on more
than simply replacing a defective compartment. There is a need
to shift the balance from damage towards resolution of inﬂam-
mation emphasising the importance of understanding the
effects of the local inﬂammatory microenvironment. Treatment
will fail if adoptively transferred Treg are inhibited or pushed
into an effector differentiation pathway by local factors in the
liver. The use of drugs that maintain Treg differentiation
including azacitidine which modulates FOXP3 DNA methylation
and the immunosuppressive mTOR inhibitor sirolimus may
facilitate Treg stability in vivo [20]. Another important factor
is whether therapeutic Treg need to be antigen-speciﬁc; if so,
such an approach is possible in type 2 AIH where the antigen
is known but not in type 1 AIH or other autoimmune liver dis-
eases where the antigen is unknown. Here, one has to hope
that polyclonal Treg will be effective. Finally, we need to know
how to deliver Treg and whether we want them to exert their
action in lymphoid tissue or within the liver itself. Although
there are challenges, the recent study showing that IL-2 infu-
sions can mediate immunosuppressive activity associated with
increased circulating Treg in HCV-related vasculitis provides
encouragement to pursue Treg therapy in autoimmune liver
disease [21].Conﬂict of interest
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